Chemiluminescence Immunoassay Analyzers Market

Rising prevalence of chronic diseases to boost market growth

The increasing incidence of chronic diseases such as cancer, cardiovascular diseases, and infectious diseases is driving the demand for CLIA analyzers. These analyzers help in the accurate diagnosis and monitoring of these diseases, which is essential for effective treatment. The development of advanced CLIA analyzers that offer faster and more accurate results is driving their adoption. These analyzers also offer features such as automation, high throughput, and connectivity, which enhance their usability and efficiency.

Increasing demand for point-of-care testing The growing demand for point-of-care testing is also driving the growth of the CLIA analyzers market. CLIA analyzers are widely used in point-of-care testing as they offer rapid and accurate results, which is crucial in emergency situations. Governments around the world are investing heavily in healthcare infrastructure and research and development activities, which is boosting the growth of the CLIA analyzers market. 

Additionally, favorable reimbursement policies are also encouraging the adoption of CLIA analyzers. The aging population is more susceptible to chronic diseases, which is driving the demand for CLIA analyzers. These analyzers are essential in the early diagnosis and management of these diseases, which is crucial for improving patient outcomes.

The Global Chemiluminescence Immunoassay (CLIA) Analyzers Market Industry experiences a surge in demand for diagnostic testing, driven by the increasing prevalence of chronic diseases and the need for early detection. As healthcare systems globally prioritize preventive care, the adoption of CLIA analyzers is likely to rise. In 2024, the market is projected to reach 13.6 USD Billion, reflecting a growing reliance on accurate and efficient diagnostic tools. This trend is expected to continue, with the market anticipated to expand significantly, potentially reaching 29.2 USD Billion by 2035, indicating a robust growth trajectory.

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Chemiluminescence Immunoassay (CLIA) Analyzers market accounted for USD 2.51 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. North America is the largest market for CLIA analyzers due to the presence of a well-established healthcare infrastructure, increasing geriatric population, and favorable reimbursement policies. The US and Canada are the major contributors to the growth of the market in this region. 

Further, the US Chemiluminescence Immunoassay (CLIA) Analyzers market held the largest market share, and the Canada Chemiluminescence Immunoassay (CLIA) Analyzers market was the fastest growing market in the North American region.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 Chemiluminescence Immunoassay (CLIA) Analyzers Market Share by Region 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Chemiluminescence Immunoassay (CLIA) Analyzers market accounts for the second-largest market share. Europe is the second-largest market for CLIA analyzers due to the increasing prevalence of chronic diseases, rising demand for point-of-care testing, and increasing healthcare spending. The UK, Germany, and France are the major contributors to the growth of the market in this region.

The Asia-Pacific Chemiluminescence Immunoassay (CLIA) Analyzers market is expected to grow at the fastest CAGR from 2022 to 2030. Due to the increasing awareness about early disease diagnosis, rising healthcare expenditure, and increasing demand for advanced medical technologies. China, India, and Japan are the major contributors to the growth of the market in this region. Moreover, China Chemiluminescence Immunoassay (CLIA) Analyzers market held the largest market share, and the India Chemiluminescence Immunoassay (CLIA) Analyzers market was the fastest growing market in the Asia-Pacific region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the Chemiluminescence Immunoassay (CLIA) Analyzers market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Chemiluminescence Immunoassay (CLIA) Analyzers industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the Chemiluminescence Immunoassay (CLIA) Analyzers industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Chemiluminescence Immunoassay (CLIA) Analyzers industry has provided innovative products with some of the most significant benefits. 

The Chemiluminescence Immunoassay (CLIA) Analyzers market major player such as Abbott, Hoffmann-La Roche Ltd, Siemens Healthcare GmbH (Siemens AG), Danaher (Beckman Coulter Inc.), DiaSorin S.p.A., Ortho Clinical Diagnostics (Part of Carlyle Group), Shenzhen New Industries Biomedical Engineering Co.Ltd., Sysmex Corporation, Randox Laboratories Ltd., Tosoh Corporation, and others are working to expand the market demand by investing in research and development activities.

Abbott Laboratories is a healthcare company that develops and manufactures a wide range of products, including diagnostic tests, medical devices, and nutritional products. The company is a leading player in the CLIA analyzer market, offering a range of high throughput analyzers and assays for infectious diseases, oncology, cardiac markers, and more. 

In recent news related to CLIA analyzers, Abbott announced in November 2021 that its Architect i1000SR and i2000SR analyzers received CE Mark approval for a new quantitative test for the detection of antibodies to the SARS-CoV-2 virus, the causative agent of COVID-19. The test, called SARS-CoV-2 IgG Quant II, is designed to measure the level of antibodies present in a patient's blood, which can help in assessing their immune response to the virus. 

The test is highly sensitive and specific, and has a broad dynamic range, allowing for accurate detection and quantification of antibodies in both vaccinated and unvaccinated individuals. The approval of this test is significant, as it can help in monitoring the immune response to COVID-19 vaccines and in identifying individuals who may require booster doses.

Siemens Healthineers is a medical technology company that offers a range of products and services, including diagnostic imaging and laboratory diagnostics. The company is also a leading player in the CLIA analyzer market, offering a range of high-performance systems and assays. In recent news related to CLIA analyzers, Siemens Healthineers announced in December 2021 that it received CE Mark approval for a new high-throughput analyzer, the Atellica VTLi Patient-Side Immunoassay Analyzer. 

The analyzer is designed for use in point-of-care settings, such as emergency departments and intensive care units, and can deliver results in as little as 10 minutes. The Atellica VTLi analyzer offers a broad menu of immunoassays for infectious diseases, cardiac markers, and inflammation, among others. The analyzer uses chemiluminescence technology for reliable and sensitive detection of analytes, and has a throughput of up to 400 tests per hour. 

The approval of this analyzer is significant, as it can help in improving patient outcomes by providing fast and accurate diagnostic information in critical care settings.